List of Excipients in Branded Drug OXYCODONE HYDCHLORIDE

« Back to Dashboard

Generic Drugs Containing OXYCODONE HYDCHLORIDE

Company	Ingredient	NDC	Excipient
Quality Care Products LLC	oxycodone hydchloride	35356-839	CELLULOSE, MICROCRYSTALLINE
Quality Care Products LLC	oxycodone hydchloride	35356-839	D&C RED NO. 27
Quality Care Products LLC	oxycodone hydchloride	35356-839	LACTOSE MONOHYDRATE
Quality Care Products LLC	oxycodone hydchloride	35356-839	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in OXYCODONE HYDCHLORIDE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	D&C RED NO. 27
2	LACTOSE MONOHYDRATE
2	SILICON DIOXIDE

Oxycodone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 15, 2026

Oxycodone hydrochloride is a mature opioid active pharmaceutical ingredient with limited opportunity in undifferentiated immediate-release tablets. The strongest commercial opportunities are in abuse-deterrent delivery, multiparticulate extended release, abuse-resistant capsules, pediatric and geriatric dosage forms, preservative-free injectable products, and excipient platforms that improve manufacturability or reduce variability.

The largest barriers are FDA scrutiny of opioid abuse-deterrence claims, established generic competition, controlled-substance compliance, product-liability exposure, and patent estates around branded extended-release technologies.

What is oxycodone hydrochloride and how does it differ from oxycodone base?

Oxycodone hydrochloride is the hydrochloride salt of oxycodone used in immediate-release tablets, capsules, oral solutions, and injectable products. Oxycodone base is used in some extended-release technologies, including products that encapsulate or embed oxycodone in multiparticulate systems.

Attribute	Oxycodone hydrochloride	Oxycodone base
Chemical form	Hydrochloride salt	Free base
Common use	Immediate-release oral and injectable products	Certain controlled-release multiparticulate systems
Water solubility	Relatively high	Lower than the hydrochloride salt
Formulation role	Enables rapid dissolution and solution manufacture	Can support hydrophobic matrix or lipid-based release control
Commercial examples	Roxicodone, generic oxycodone tablets, oral solutions, injection	Xtampza ER uses oxycodone in DETERx microspheres
Primary formulation challenge	Dose dumping, abuse by crushing or extraction	Release control, content uniformity, food effect, manufacturing complexity

Salt selection directly affects dissolution, dose uniformity, solution processing, and abuse-deterrence design. A developer cannot assume that an excipient platform validated for oxycodone base will transfer directly to oxycodone hydrochloride.

What excipients are used in oxycodone hydrochloride products?

Immediate-release oxycodone hydrochloride tablets generally use conventional fillers, binders, disintegrants, lubricants, glidants, and film-coating systems.

Excipient function	Typical candidate materials	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet size and compression
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling friction
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose, polyvinyl alcohol	Protects tablet and supports identification
Opacifier or colorant	Titanium dioxide, iron oxides, approved lake colors	Product differentiation and identification
Sweetener and flavor	Sucralose, saccharin sodium, flavors	Taste masking in oral liquids or orally disintegrating products
Suspending agent	Xanthan gum, sodium carboxymethylcellulose, hypromellose	Maintains dose uniformity in liquids
Preservative	Sodium benzoate, parabens, benzyl alcohol where appropriate	Microbial control in multidose liquids

Excipient selection must account for opioid potency. A small absolute blend error can produce a clinically meaningful dose variation. Low-dose formulations therefore require high-flow, low-segregation excipient systems and robust blend-uniformity controls.

Which excipients are most valuable in immediate-release tablets?

The highest-value excipient improvements are usually manufacturing improvements rather than new pharmacology. Direct-compression grades of microcrystalline cellulose, co-processed excipients, spray-dried lactose, and low-friction lubricants can reduce segregation, compression defects, and batch failure.

A commercial excipient platform is more attractive if it provides:

• Consistent content uniformity at low drug loadings.
• Lower lubricant sensitivity.
• High tablet tensile strength at low compression force.
• Rapid disintegration without excessive friability.
• Compatibility with colored or imprintable film coatings.
• Reduced dust generation during controlled-substance manufacturing.
• Robust performance across multiple tablet strengths.

A generic manufacturer may obtain greater value from a validated platform formulation than from a novel excipient claim that does not create meaningful regulatory or manufacturing differentiation.

What formulation patents protect oxycodone hydrochloride products?

Patent protection in oxycodone is concentrated in product-specific release technologies, abuse-deterrent systems, manufacturing processes, and method-of-use claims. Basic immediate-release oxycodone hydrochloride tablet technology is generally mature and exposed to generic competition.

Patent category	Typical protected subject matter	Commercial effect
Extended-release matrix	Polymer matrices, release profiles, dose proportionality	Can delay generic substitution
Multiparticulate delivery	Drug-loaded microspheres, pellets, coated particles	Protects release control and capsule filling
Abuse deterrence	Crush-resistant matrices, gelling systems, extraction-resistant particles	Supports labeling and product differentiation
Capsule systems	Multi-compartment capsules, coated beads, tamper-resistant fills	Creates device and formulation barriers
Method of use	Dosing schedules, abuse-deterrent administration, patient populations	May support narrower patent protection
Manufacturing	Spray congealing, coating, particle engineering, granulation	Can complicate non-infringing manufacture
Packaging	Unit-dose, lockable, tamper-evident or compliance packaging	Usually provides secondary protection rather than core exclusivity

What is the Orange Book status of oxycodone products?

FDA Orange Book status depends on the specific product and applicant. Generic immediate-release oxycodone hydrochloride products are generally listed as therapeutically equivalent to their reference products when FDA assigns an AB rating. Branded extended-release and abuse-deterrent products may have active patents or exclusivity entries that do not apply to conventional immediate-release generics.

The relevant FDA categories are:

1. Oxycodone hydrochloride immediate-release tablets.
2. Oxycodone hydrochloride oral solutions.
3. Oxycodone hydrochloride injection.
4. Oxycodone hydrochloride extended-release tablets.
5. Abuse-deterrent extended-release oxycodone products.
6. Combination products containing oxycodone and acetaminophen or other active ingredients.

FDA's Orange Book must be reviewed by application number because listing status, patent expiration, and therapeutic-equivalence codes differ by dosage form and strength. The agency's database is the controlling source for current listed patents and exclusivity entries. (FDA, 2024a)

When does oxycodone hydrochloride lose exclusivity?

Oxycodone hydrochloride immediate-release products have already experienced extensive generic entry. Their principal commercial protection is not basic composition-of-matter exclusivity but manufacturing scale, supply reliability, controlled-substance distribution capability, and customer contracts.

Extended-release products have had longer protection because of formulation and abuse-deterrence patents. The timing of generic entry depends on:

• The specific reference-listed drug.
• Active Orange Book patents.
• Paragraph IV certifications.
• FDA approval timing.
• Whether the generic copies the abuse-deterrent formulation or seeks approval as a conventional product.
• Litigation settlements and permitted launch dates.
• Whether a product has separate patents covering strengths, release profiles, or manufacturing methods.

A paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act. If suit is filed within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments. (FDA, 2024b; 21 U.S.C. § 355)

What patent expiration dates matter most?

The key dates are product-specific. Older immediate-release oxycodone patents have largely expired. Commercially relevant dates for extended-release products are tied to formulation and abuse-deterrence patents rather than the oxycodone molecule itself.

A due-diligence review should identify:

Date	Why it matters
Original NDA approval	Establishes reference-product history
New chemical entity exclusivity end	Usually historical for oxycodone
Pediatric exclusivity end	Can add six months to relevant exclusivity
Orange Book patent expiration	May restrict approval or launch
Patent terminal disclaimer date	May shorten effective patent term
Settlement launch date	Can create a practical generic-entry date
30-month stay expiration	May permit FDA approval absent other barriers
Regulatory exclusivity expiration	Determines approval timing independent of patents

Exact expiration dates should be taken from the current FDA Orange Book and patent records because historical patent families can include continuations, reissues, terminal disclaimers, and patent-term adjustments.

What excipient strategies create abuse-deterrent commercial opportunities?

Abuse-deterrent formulation is the most important differentiated excipient opportunity in oxycodone.

FDA recognizes several abuse-deterrence mechanisms:

• Physical and chemical barriers.
• Agonist-antagonist combinations.
• Aversion through unpleasant effects.
• Delivery-system barriers.
• Novel approaches that reduce abuse through formulation design.

For oxycodone, excipient and process strategies include:

Crush-resistant matrices

High-viscosity polymers, waxes, hydrophobic binders, and high-compression matrices can make tablets difficult to pulverize. The objective is not merely higher tablet hardness. Excessive hardness can impair dissolution and create unacceptable release variability.

Relevant design parameters include:

• Particle size after crushing.
• Powderability under common household tools.
• Drug release after chewing or grinding.
• Alcohol sensitivity.
• Extraction yield in aqueous and organic media.
• Stability after thermal stress.
• Manufacturability at commercial scale.

Gelling and viscosity-building systems

Hydrophilic polymers can form viscous gels when contacted with water. This may reduce syringeability and limit extraction. Candidate materials include high-viscosity hypromellose, polyethylene oxide, carbomers, and selected cellulose ethers.

The principal development risks are:

• Delayed dissolution under intended oral use.
• Unacceptable mouthfeel.
• Variable gel formation across pH conditions.
• High sensitivity to ionic strength.
• Difficult tablet compression.
• Potential dose dumping after mechanical disruption.

Multiparticulate systems

Drug-loaded pellets or microspheres can provide release control while reducing the value of crushing a single tablet. Coatings may use ethylcellulose, polymethacrylates, hypromellose, or lipid materials.

Multiparticulate systems can improve:

• Dose proportionality.
• Release-profile control.
• Capsule filling flexibility.
• Resistance to simple crushing.
• Combination of immediate-release and extended-release fractions.

They also increase manufacturing complexity, including coating uniformity, residual solvent controls, particle segregation, and capsule content uniformity.

Lipid and hydrophobic excipient platforms

Lipids, waxes, fatty alcohols, and hydrophobic polymers can reduce aqueous extraction and moderate drug release. These systems require careful control of:

• Polymorphic transitions.
• Oxidative stability.
• Food effects.
• Dissolution sensitivity to surfactants.
• Scale-up heat transfer.
• Long-term release stability.

The commercial value is highest where the platform produces a clinically acceptable extended-release profile and a credible abuse-deterrence profile without requiring a new active ingredient.

What formulations are protected by branded oxycodone products?

OxyContin

OxyContin is an extended-release oxycodone product marketed by Purdue Pharma. FDA has described the reformulated product as having abuse-deterrent properties under physical and chemical manipulation testing. Its formulation uses a controlled-release matrix rather than a conventional immediate-release tablet. (FDA, 2024c)

The commercial barrier is a combination of formulation know-how, regulatory history, manufacturing controls, and patent rights. A generic applicant may avoid some claims by pursuing a conventional extended-release formulation, but it may then lack equivalent abuse-deterrent labeling.

Xtampza ER

Xtampza ER, marketed by Collegium Pharmaceutical, uses the DETERx technology platform. The product contains oxycodone in microspheres designed to provide extended release and resist common manipulation methods. The platform also addresses alcohol-related dose dumping and food-effect requirements. (FDA, 2016)

Its commercial protection is based on multiparticulate manufacturing, microsphere structure, release control, and product-specific regulatory evidence. DETERx has broader platform potential than a single tablet matrix, but the manufacturing process is more complex.

Oxaydo

Oxaydo is an immediate-release oxycodone product with abuse-deterrent labeling based on a physical and chemical barrier. The product is designed to resist crushing and snorting, although abuse-deterrent labeling does not eliminate abuse or prevent all routes of misuse. (FDA, 2015)

This category creates opportunities for high-hardness tablets, tamper-resistant matrices, and excipient systems that preserve rapid intended oral release.

Which companies are challenging oxycodone patents?

The competitive field includes:

• Large generic manufacturers with controlled-substance infrastructure.
• Specialty generic companies targeting abuse-deterrent formulations.
• Branded opioid manufacturers with proprietary delivery platforms.
• Excipient suppliers offering polymer, coating, and multiparticulate technologies.
• Contract development and manufacturing organizations with opioid handling licenses.

Paragraph IV activity is product-specific and changes as patents expire, are delisted, settle, or are invalidated. FDA's Drugs@FDA records, Orange Book, USPTO Patent Center, and federal court dockets are the relevant sources for identifying current challengers and litigation status. (FDA, 2024a; USPTO, 2024)

A generic company with a conventional immediate-release product has a different risk profile from a company seeking an abuse-deterrent extended-release product. The latter may face formulation patents, process patents, clinical or human-factors evidence requirements, and a higher regulatory burden.

What is the litigation and settlement risk for oxycodone products?

Oxycodone litigation has involved product liability, opioid marketing, patent disputes, and regulatory issues. For a formulation developer, the main commercial risks are:

1. Paragraph IV patent litigation against an extended-release reference product.
2. Infringement claims against coating, matrix, or microsphere processes.
3. Product-liability claims related to misuse, diversion, overdose, or inadequate warnings.
4. State and federal controlled-substance compliance actions.
5. Manufacturing deviations affecting potency or release.
6. Contract disputes involving active pharmaceutical ingredient supply or controlled-substance quotas.

Settlement agreements can establish an authorized generic arrangement, a delayed generic launch, a license under selected patents, or a launch date before patent expiration. The practical entry date may therefore differ from the nominal Orange Book expiration date.

What FDA regulatory status applies to oxycodone hydrochloride excipient products?

Oxycodone products are approved under the Federal Food, Drug, and Cosmetic Act and are subject to controlled-substance requirements under the Controlled Substances Act. Oxycodone is a Schedule II controlled substance in the United States.

The regulatory pathway depends on the product:

Product type	Likely pathway
Conventional generic tablet	ANDA under section 505(j)
Generic oral solution	ANDA, with concentration and inactive-ingredient controls
New abuse-deterrent formulation	NDA under section 505(b)(1) or 505(b)(2), depending on reliance strategy
New extended-release product	NDA or 505(b)(2), with release and abuse-deterrence evidence
Injectable product	ANDA if pharmaceutically equivalent, otherwise NDA or 505(b)(2)
Novel excipient use	Requires safety justification and may increase regulatory burden

FDA does not approve an excipient as an independent therapeutic product. The excipient is assessed as part of the finished dosage form. Novel excipient use can require toxicology, local-tolerance, extractables and leachables, impurity, and compatibility data.

Abuse-deterrent labeling requires evidence under FDA's abuse-deterrent opioid guidance. In vitro manipulation studies alone generally do not establish that a product reduces abuse in the population. Human abuse-potential studies and postmarketing data may be relevant depending on the claim. (FDA, 2015; FDA, 2020)

What commercial opportunities exist for oxycodone hydrochloride excipients?

1. Low-dose content-uniformity platforms

Excipient suppliers can offer co-processed systems that reduce segregation and improve blend uniformity across 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. This opportunity is commercially practical because generic manufacturers value lower batch rejection rates and easier scale-up.

2. Abuse-deterrent tablet matrices

A polymer-lipid system that combines crush resistance, rapid intended dissolution, low extraction yield, and manageable compression is commercially differentiated. The strongest value proposition is a platform that can be adapted to multiple opioid actives.

3. Multiparticulate coating systems

Drug-layering and functional-coating technologies can support extended-release oxycodone products without relying on a single monolithic tablet. Coating uniformity and scale-up know-how can create a meaningful manufacturing barrier.

4. Pediatric and geriatric products

Oral liquids, mini-tablets, sprinkle capsules, and taste-masked granules remain technically attractive. Commercial development must address dose flexibility, accidental ingestion, caregiver handling, and diversion risk.

Taste masking is difficult because oxycodone is pharmacologically active at low doses and can create strong sensory exposure if the formulation is chewed or held in the mouth. Ion-exchange resins, polymer coatings, lipid barriers, and multiparticulate encapsulation are potential approaches.

5. Preservative-free injectable systems

Oxycodone hydrochloride injection is an opportunity for ready-to-use, low-particulate, preservative-free presentations. Value can come from container-closure compatibility, reduced adsorption, low extractables, and simplified hospital preparation.

6. Tamper-evident packaging and unit-dose delivery

Packaging does not replace formulation-based abuse deterrence, but unit-dose blister systems, senior-friendly closures, and diversion-resistant distribution can support institutional markets. The opportunity is strongest in hospitals, surgery centers, and specialty pharmacies.

7. Continuous manufacturing and controlled-substance containment

Excipient systems compatible with continuous blending, low-dust handling, and high-containment processing can reduce operator exposure and improve batch traceability. This is a manufacturing opportunity rather than a conventional patent opportunity.

How does oxycodone compare with other opioid formulation markets?

Market	Generic pressure	Excipient differentiation	Regulatory burden	Commercial attractiveness
Immediate-release oxycodone	High	Low to moderate	Moderate	Selective
Extended-release oxycodone	Moderate	High	High	High if patentable
Abuse-deterrent oxycodone	Lower than conventional IR	Very high	Very high	High risk, high value
Hydromorphone IR	High	Moderate	Moderate	Limited
Buprenorphine sublingual	Moderate	High for transmucosal delivery	High	Attractive
Tramadol oral products	High	Moderate	Moderate	Moderate
Injectable opioids	Moderate	Moderate	High manufacturing controls	Selective

Oxycodone offers a larger commercial base than many opioid products, but it also attracts more regulatory scrutiny and liability exposure. The best excipient opportunity is a platform that reduces abuse potential while preserving predictable therapeutic release.

What generic launch scenarios exist for oxycodone hydrochloride?

Conventional immediate-release launch

This is the lowest-barrier scenario. A manufacturer uses established excipients and seeks ANDA approval with therapeutic equivalence. Competition is primarily based on price, supply continuity, quality history, and wholesaler access.

Extended-release non-abuse-deterrent launch

A company may develop an extended-release product without seeking abuse-deterrent labeling. It must still establish bioequivalence, release control, alcohol robustness, food-effect performance, and dose proportionality. Patent and regulatory risk remain substantial.

Abuse-deterrent extended-release launch

This scenario requires the most differentiated technology. The product must address manipulation, extraction, snorting, injection, and potentially oral overconsumption depending on the proposed labeling. It requires substantial formulation and analytical investment.

Authorized-generic or licensed launch

A generic manufacturer may enter through a license, supply arrangement, or authorized-generic structure. This can reduce patent risk but may compress margins and limit control over commercial positioning.

How strong is the patent estate for oxycodone hydrochloride?

The patent estate is weak for conventional immediate-release oxycodone hydrochloride and stronger for proprietary extended-release and abuse-deterrent systems.

Segment	Patent strength	Main reason
Basic oxycodone hydrochloride tablet	Low	Mature chemistry and extensive generic entry
Conventional oral solution	Low to moderate	Formulation and concentration claims may remain
Extended-release matrix	Moderate to high	Release profile and matrix claims
Multiparticulate microspheres	High	Particle architecture and process complexity
Abuse-deterrent product	High	Combination of formulation, process, and regulatory evidence
Novel excipient platform	Variable	Depends on composition, use, and freedom to operate
Packaging-only innovation	Low to moderate	Often easier to design around

Patent strength should be assessed claim by claim. A broad composition claim covering a functional matrix is more valuable than a narrow claim limited to a single excipient ratio or process parameter. Freedom-to-operate analysis must include continuation applications and unpublished applications where available through prosecution history and assignment records.

What geographic markets offer the best opportunities?

The United States offers the largest commercial opportunity for abuse-deterrent opioid technology but also has the highest regulatory and litigation burden. Canada, Australia, and selected European markets may offer opportunities for controlled-release or hospital products, but opioid prescribing volumes, reimbursement, and abuse-deterrence requirements differ.

A global excipient platform should be designed around:

• Pharmacopoeial compliance in the target markets.
• Regional excipient restrictions.
• Controlled-substance import and export permits.
• Differences in food-effect requirements.
• Local packaging and serialization rules.
• Regional patent coverage.
• Country-specific product liability exposure.

U.S. patent protection does not establish freedom to operate in Europe, Canada, Japan, or emerging markets. Patent families should be mapped by jurisdiction, continuation status, national phase, and terminal disclaimer.

What revenue exposure does oxycodone create?

Revenue exposure is concentrated in branded extended-release products and high-volume generic immediate-release products. For excipient suppliers, the addressable market is smaller than the active pharmaceutical ingredient market but can support premium pricing when the excipient is tied to:

• A proprietary abuse-deterrent platform.
• A difficult-to-replicate coating or microsphere process.
• A validated low-dose content-uniformity system.
• A hospital injectable presentation.
• A formulation with regulatory or patent differentiation.

The highest-margin opportunity is usually a platform sold under a technical agreement with formulation support, not a commodity excipient sold solely by kilogram.

Key Takeaways

• Oxycodone hydrochloride immediate-release products are mature and heavily exposed to generic competition.
• The strongest excipient opportunity is abuse-deterrent extended-release delivery.
• Multiparticulate microspheres, crush-resistant matrices, gelling systems, and extraction-resistant coatings have the greatest differentiation potential.
• Low-dose content uniformity, taste masking, pediatric dosing, and preservative-free injection are practical secondary opportunities.
• OxyContin, Xtampza ER, and Oxaydo represent distinct formulation and regulatory strategies.
• Orange Book status, patent expiration, paragraph IV activity, and settlements must be reviewed by product and application number.
• Novel excipient use increases regulatory and toxicology requirements.
• The commercial value of an excipient platform depends on patent scope, FDA labeling potential, scale-up performance, and freedom to operate.
• Geographic expansion requires separate patent, controlled-substance, regulatory, and reimbursement analysis.

FAQs

Can standard tablet excipients be used in oxycodone hydrochloride generics?

Yes. Conventional fillers, binders, disintegrants, lubricants, and film-coating materials can be used if the finished product meets quality, bioequivalence, potency, dissolution, and stability requirements.

Is oxycodone hydrochloride suitable for an orally disintegrating tablet?

Yes, but taste masking, dose uniformity, abuse risk, and accidental exposure are major development constraints. Multiparticulate encapsulation and ion-exchange or polymer barriers may be required.

Do abuse-deterrent excipients prevent opioid abuse?

No. They are intended to make specific forms of manipulation more difficult or less rewarding. Abuse-deterrent labeling does not establish that all abuse, overdose, or diversion is prevented.

Can a generic oxycodone product use the same excipients as OxyContin?

A generic may use similar excipients, but it must satisfy applicable sameness, safety, bioequivalence, release, and labeling requirements. Similar excipient selection does not eliminate formulation patent or process patent risk.

What is the best commercial entry point for a new oxycodone excipient platform?

A validated abuse-deterrent multiparticulate or matrix platform has the highest potential value. A low-dose content-uniformity platform offers a lower-risk opportunity but is more exposed to price competition.

References

1. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling

2. U.S. Food and Drug Administration. (2015). FDA approves new oxycodone product with abuse-deterrent properties. https://www.fda.gov/news-events/press-announcements/fda-approves-new-oxycodone-product-abuse-deterrent-properties

3. U.S. Food and Drug Administration. (2016). FDA approves extended-release oxycodone with abuse-deterrent properties. https://www.fda.gov/news-events/press-announcements/fda-approves-extended-release-oxycodone-abuse-deterrent-properties

4. U.S. Food and Drug Administration. (2020). General principles for evaluating abuse-deterrence of orally administered opioid drug products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-evaluating-abuse-deterrence-orally-administered-opioid-drug-products

5. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (2024b). ANDA submissions: Content and format. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-content-and-format

7. U.S. Food and Drug Administration. (2024c). OxyContin prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

8. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

9. Controlled Substances Act, 21 U.S.C. §§ 801-971.

10. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.